This competing renewal proposes to define the recommended phase II dose and toxicities of new antineoplastic agents, including approaches to amelioration of such toxicity;to define the pharmacokinetics, pharmacodynamics, and pharmacogenetics of new antineoplastic agents;to develop new combinations that enhance the therapeutic index and/or oral bioavailability of new or established agents;and to develop and implement novel methodological approaches to phase I studies. This application includes four ongoing studies: 1) XK469 as a single dose every 3 weeks, 2) cilengitide by prolonged continuous infusion, 3) PXD101 and 5-azacitidine in leukemia, and 4) a randomized dose-escalation study of sorafenib using 12- hour ambulatory blood pressure monitoring as a biomarker. These studies build on the applicants'prior experience with these and related drugs. New studies will be proposed, as based upon the availability of new agents (in response to NCI requests for Letters of Intent). In addition, unsolicited Letters of Intent will be submitted, as determined by the scientific interests of the applicants. Particular areas of expertise and interest include pharmacogenetics and noninvasive biomarkers (such as ambulatory blood pressure monitoring or serum measurements of tyrosine kinase receptors). Most of the studies will evaluate novel therapies in patients with advanced solid tumors. In addition, the applicants anticipate maintaining at least one ongoing study for patients with advanced hematologic malignancies, and at least one study that is open to older children (minimum age 14 years or weight of 45 kg or more). All of the proposed studies will include pharmacokinetic or correlative components. The latter will include pharmacodynamic studies of tumor and normal tissue evaluating signal transduction endpoints, as well as pharmacogenetic studies. The proposed pharmacogenetic studies will be performed in collaboration with the Pharmacogenetics of Anticancer Agents Research (PAAR) Group, chaired by the Principal Investigator. The PAAR Group is part of a larger NIH Pharmacogenetics Research Network, administered through NIGMS. The applicants will also participate in the Investigational Drug Steering Committee and its Task Forces.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA069852-18
Application #
8225389
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (O1))
Program Officer
Ivy, S Percy
Project Start
1995-05-10
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2014-02-28
Support Year
18
Fiscal Year
2012
Total Cost
$780,769
Indirect Cost
$272,125
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Maitland, Michael L; Xu, Chun-Fang; Cheng, Yu-Ching et al. (2015) Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res 21:365-72
Odenike, Olatoyosi; Halpern, Anna; Godley, Lucy A et al. (2015) A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs 33:371-9
Geeleher, Paul; Loboda, Andrey; Lenkala, Divya et al. (2015) Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J Natl Cancer Inst 107:
O'Donnell, Peter H; Karovic, Sanja; Karrison, Theodore G et al. (2015) Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res 21:5092-9
Karovic, S; Wen, Y; Karrison, T G et al. (2014) Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther 96:27-35
Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32
Paller, Channing J; Bradbury, Penelope A; Ivy, S Percy et al. (2014) Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res 20:4210-7
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Sharma, Manish R; Karrison, Theodore G; Kell, Bethany et al. (2013) Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res 19:3059-67
O'Donnell, Peter H; Undevia, Samir D; Stadler, Walter M et al. (2012) A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs 30:604-10

Showing the most recent 10 out of 37 publications